The acute myeloid leukemia (AML) field has witnessed rapid evolution of late, with exciting developments in strategies for the treatment of the disease. 

In this podcast, Naval Daver, MD, University of Texas MD Anderson Cancer Center, Houston, TX,  chairs a discussion with Marion Subklewe, MD, LMU Hospital Munich, Munich, Germany, Amir Fathi, MD, MPH, Massachusetts General Hospital, Boston, MA, and Andrew Wei, MBBS, PhD, Alfred Hospital and Monash University, Melbourne, Australia. The spreakers debate the key updates in the treatment of AML from the recent ASCO and EHA 2020 virtual meetings including emerging immunotherapies, venetoclax-based regimens and targeted therapies in AML.

The post The AML Sessions: emerging immunotherapies, venetoclax-based regimens and targeted therapies in AML appeared first on VJHemOnc.